ADVANTAGENE, INC

Company Information

Company Name
ADVANTAGENE, INC
Address
440 Lexington St
AUBURNDALE, MA, 02466-1923
Phone
n/a
URL
n/a
DUNS
192959851
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$2,145,770.00
6
SBIR Phase II
$9,319,195.00
2

Award List

  1. Combination of GM-CSF with TKR gene therapy

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Combined gene therapy (Herpes Simplex Virus Thymidine Kinase + Anti-herpetic Prodrug) and radiation therapy (TKR therapy) is a novel approach in the armamentarium ...

    SBIR Phase I 2003 Department of Health and Human Services
  2. Clinical study of AdV-tk radiogene therapy for glioma

    Amount: $758,386.00

    DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic appr ...

    SBIR Phase I 2004 Department of Health and Human Services
  3. Clinical study of GMCI in Pancreatic Cancer

    Amount: $747,384.00

    DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the US; with less than one-year median survival, it accounts for approximately 30,000 dia ...

    SBIR Phase I 2006 Department of Health and Human Services
  4. Improved system for producing adenoviral vectors

    Amount: $213,871.00

    First generation non-replicative adenoviral vectors show promise as anti-cancer agents and as prophylactic vaccines. Current methods for manufacturing these vectors use either the 293 cell line or t ...

    SBIR Phase I 2007 Department of Health and Human Services
  5. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

    Amount: $101,130.00

    DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a ...

    SBIR Phase I 2007 Department of Health and Human Services
  6. Clinical study of AdV-tk radiogene therapy for malignant glioma

    Amount: $2,092,604.00

    DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic appr ...

    SBIR Phase II 2007 Department of Health and Human Services
  7. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

    Amount: $7,226,591.00

    DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a ...

    SBIR Phase II 2009 Department of Health and Human Services
  8. Clinically suitable approach for gene-mediated therapy of cirrhosis.

    Amount: $224,999.00

    Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhos ...

    SBIR Phase I 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government